RECOMBINANT ONCOLYTIC VIRUSES FOR CANCER THERAPY
The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the u...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French |
Published |
05.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The disclosure provides a recombinant oncolytic poxvirus including vaccinia virus comprising one or more inactivated immunomodulatory gene selected from NIL, K1L, K3L, A46R, and/or A52R, optionally further comprising inactivated TK and/or VGF genes. The disclosure also provides methods and for the use of these recombinant oncolytic poxvirus in oncolytic virotherapy. Also provided in the disclosure are vector constructs for generating recombinant oncolytic poxviruses including for example vaccinia viruses that have one or more inactivated immunomodulatory genes.
L'invention concerne un poxvirus oncolytique recombiné comprenant un virus de la vaccine comprenant un ou plusieurs gènes immunomodulateurs inactivés choisis parmi NIL, K1L, K3L, A46R et/ou A52R, comprenant en outre éventuellement des gènes TK et/ou VGF inactivés. L'invention concerne également des procédés et l'utilisation de ces poxvirus oncolytiques recombinés dans une virothérapie oncolytique. L'invention concerne également des constructions de vecteur permettant de générer des poxvirus oncolytiques recombinés comprenant, par exemple, des virus de la vaccine qui ont un ou plusieurs gènes immunomodulateurs inactivés. |
---|---|
Bibliography: | Application Number: WO2017CA51171 |